{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:25:59Z","timestamp":1793330759273,"version":"4.5.0"},"reference-count":44,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Abiraterone acetate (AA) is widely used for metastatic castration-resistant prostate cancer (mCRPC), but the standard dose (1000 mg fasting) imposes challenges in resource-constrained settings due to strict fasting requirements and financial toxicity. Pharmacokinetic (PK) studies suggest that low-dose AA (250 mg with a low-fat meal) may provide comparable drug exposure, although clinical evidence remains limited. This trial compared the clinical efficacy of low-dose versus standard-dose AA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\n                      This multicenter, open-label, phase III, noninferiority trial randomly assigned patients with mCRPC, 1:1, to low-dose or standard-dose AA. The primary end point was prostate-specific antigen progression-free survival (PSA-PFS). Secondary\/exploratory end points included PSA\n                      <jats:sub>30<\/jats:sub>\n                      \/PSA\n                      <jats:sub>50<\/jats:sub>\n                      responses (% of patients with \u226530% or \u226550% reduction in PSA), radiographic PFS, overall PFS, overall survival (OS), quality of life (QoL), and PK. Planned sample size of 314 (on the basis of a noninferiority margin of hazard ratio, 1.37) was not achieved because of slow accrual, so the noninferiority hypothesis could not be tested.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      A total of 164 patients were enrolled between September 2020 and January 2025 (median age 65 years; 64.0% received prior docetaxel). PSA\n                      <jats:sub>30<\/jats:sub>\n                      and PSA\n                      <jats:sub>50<\/jats:sub>\n                      responses were 50.0% and 38.5% with low-dose AA versus 55.4% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .505) and 45.9% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .350) with standard-dose AA, respectively. Median follow-up was 17.5 months. Median PSA-PFS was 5.7 months with low-dose versus 3.8 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .830) with standard-dose AA. Median OS was 18.1 versus 15.8 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .976). Grade \u22653 toxicities occurred in 38.3% versus 30.0% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .269), respectively. PK analyses demonstrated approximately 8-fold higher AA exposure with standard dose. QoL scores were comparable between arms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Although underpowered to prove noninferiority, low-dose AA with food yielded outcomes broadly similar to standard dosing, with maintained safety and QoL. This cost-conscious regimen may be a feasible alternative, supporting further confirmatory evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/go-25-00505","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:59:12Z","timestamp":1776974352000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial"],"prefix":"10.1200","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0191-2744","authenticated-orcid":true,"given":"Vanita","family":"Noronha","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-9555","authenticated-orcid":true,"given":"Minit","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-2631","authenticated-orcid":true,"given":"Akhil","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha Cancer Hospital, Varanasi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4214-5799","authenticated-orcid":true,"given":"Nandini","family":"Menon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7691-3995","authenticated-orcid":true,"given":"Vijay","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7167-4710","authenticated-orcid":true,"given":"Akhil Rajendra","family":"Kurup","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrit","family":"Dhar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Goud","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sucheta","family":"More","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akanksha","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1608-7780","authenticated-orcid":true,"given":"Archi","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Sable","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh","family":"Chavan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Kharghar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-6344","authenticated-orcid":true,"given":"Anupama","family":"Pradosh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Kharghar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Shirsat","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Kharghar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6348-6667","authenticated-orcid":true,"given":"Vikram","family":"Gota","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National Institute, Kharghar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9162-602X","authenticated-orcid":true,"given":"Ankush","family":"Shetake","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5701-0946","authenticated-orcid":true,"given":"Sonal","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal Krishna","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha Cancer Hospital, Varanasi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha Cancer Hospital, Varanasi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipinesh","family":"Sansar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha Cancer Hospital, Varanasi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-0481","authenticated-orcid":true,"given":"Sunita","family":"Sonawane","sequence":"additional","affiliation":[{"name":"Radiation Medical Centre, Bhabha Atomic Research Centre, Homi Bhabha National Institute, Parel, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-5004","authenticated-orcid":true,"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Parel, India"},{"name":"Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre, Muzaffarpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.ijmr_1821_22"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00471-9"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00950-8"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011"},{"key":"e_1_3_10_9_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer. Version 2.2025","author":"National Comprehensive Cancer Network","year":"2025","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer. Version 2.2025, 2025. https:\/\/www.nccn.org"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro1237"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05821.x"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm950749y"},{"key":"e_1_3_10_16_2","unstructured":"US Food and Drug Administration: FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer 2018. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-abiraterone-acetate-combination-prednisone-high-risk-metastatic-castration-sensitive"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","unstructured":"Patel A Tannock IF Srivastava P et al: Low-dose abiraterone in metastatic prostate cancer: Is it practice changing? Facts and facets. JCO Glob Oncol 10.1200\/JGO.19.00341","DOI":"10.1200\/JGO.19.00341"},{"key":"e_1_3_10_18_2","volume-title":"Summary of the Union Budget 2023-24","author":"Government of India","unstructured":"Government of India: Summary of the Union Budget 2023-24. https:\/\/www.pib.gov.in\/indexd.aspx"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.564"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.1281"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12496"},{"key":"e_1_3_10_22_2","volume-title":"Approval Package for Zytiga (abiraterone acetate)","unstructured":"Center for Drug Evaluation and Research: Approval Package for Zytiga (abiraterone acetate). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202379Orig1s005.pdf"},{"key":"e_1_3_10_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.4381"},{"key":"e_1_3_10_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"e_1_3_10_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_10_26_2","volume-title":"EORTC QLQ-C30 Scoring Manual","author":"European Organization for Research and Treatment of Cancer (EORTC)","year":"2001","unstructured":"European Organization for Research and Treatment of Cancer (EORTC): EORTC QLQ-C30 Scoring Manual (ed 3). Brussels, Belgium, EORTC, 2001. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf","edition":"3"},{"key":"e_1_3_10_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"e_1_3_10_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.059"},{"key":"e_1_3_10_29_2","article-title":"Accelerated predictive healthcare analytics with Pumas, a high-performance pharmaceutical modeling and simulation platform","author":"Rackauckas C","unstructured":"Rackauckas C, Nie Q, Ghosh A, et al: Accelerated predictive healthcare analytics with Pumas, a high-performance pharmaceutical modeling and simulation platform. arXiv https:\/\/arxiv.org\/abs\/2001.09150","journal-title":"arXiv"},{"key":"e_1_3_10_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1595"},{"key":"e_1_3_10_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2014.8"},{"key":"e_1_3_10_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.196"},{"key":"e_1_3_10_33_2","article-title":"Exploratory real-world comparative analysis of abiraterone dosing strategies","volume":"15","author":"Hulterstrum EM","year":"2025","unstructured":"Hulterstrum EM, Grindeland CJ, Czmowski M: Exploratory real-world comparative analysis of abiraterone dosing strategies. J Oncol Pharm Pract 15, 2025","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_10_34_2","doi-asserted-by":"publisher","DOI":"10.31557\/apjcb.2024.9.4.447-454"},{"key":"e_1_3_10_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01015"},{"key":"e_1_3_10_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.2509"},{"key":"e_1_3_10_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01076"},{"key":"e_1_3_10_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA2064"},{"key":"e_1_3_10_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07782-z"},{"key":"e_1_3_10_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2024.101329"},{"key":"e_1_3_10_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.08.002"},{"key":"e_1_3_10_42_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1295"},{"key":"e_1_3_10_43_2","doi-asserted-by":"publisher","unstructured":"Premnath N Sedhom R Gupta A: Potential cost savings with low-dose abiraterone in the United States. JCO Glob Oncol 10.1200\/GO.20.00140","DOI":"10.1200\/GO.20.00140"},{"key":"e_1_3_10_44_2","volume-title":"The State of Health Insurance Coverage in the U.S.: Findings from the Commonwealth Fund 2024 Biennial Health Insurance Survey (Commonwealth Fund, Nov. 2024)","author":"Collins S","unstructured":"Collins S, Gupta A: The State of Health Insurance Coverage in the U.S.: Findings from the Commonwealth Fund 2024 Biennial Health Insurance Survey (Commonwealth Fund, Nov. 2024). https:\/\/doi.org\/10.26099\/byce-qc28"},{"key":"e_1_3_10_45_2","volume-title":"Americans\u2019 Challenges with Health Care Costs","author":"Sparks G","year":"2025","unstructured":"Sparks G, Lopes L, Montero A, et al: Americans\u2019 Challenges with Health Care Costs. KFF, 2025. https:\/\/www.kff.org\/health-costs\/report\/americans-challenges-with-health-care-costs"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:59:26Z","timestamp":1776974366000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1200\/GO-25-00505"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00505","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500505"}}